Clinical Trials Logo

Detrusor Overactivity clinical trials

View clinical trials related to Detrusor Overactivity.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05572918 Not yet recruiting - Overactive Bladder Clinical Trials

Developing a Simple Test to Diagnose Overactive Bladder

Start date: December 1, 2022
Phase:
Study type: Observational

In order to develop a test to diagnose overactive bladder from urine, it is essential that this test is at least as accurate as the tools that clinicians currently use. As such, this study will compare the performance of the device in development to the performance of existing methods.

NCT ID: NCT04693897 Not yet recruiting - Clinical trials for Overactive Bladder Syndrome

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Start date: March 1, 2021
Phase:
Study type: Observational [Patient Registry]

About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects. While beta-3 adrenoceptor agonist, Mirabegron, has far fewer side effects, there are no consensus on whether it can be used as first-line treatment. The investigator's preliminary study showed that the concentration of beta-3 adrenoceptor in the urine of OAB patients is higher than that in the normal control group, so comparing urinary beta-3 adrenoceptor concentration of OAB patients before and after treatment may be used as a biomarker of therapeutic effectiveness. The results of this study will be of great help in understanding the effectiveness of Mirabegron and formulating OAB treatment plans.